Get all premium features to the best stock analysis tool

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation

Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma's more than 25 years of expertise in peptides and metabolic health with Boston's biotech innovation ecosystem.

Healthpeak Properties Closes New $400 Million Delayed-Draw Term Loan Facility

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced today that it has closed on a new $400 million unsecured delayed-draw term loan facility (“Term Loan”). “This new term loan enhances our liquidity and financial flexibility and further strengthens our balance sheet,” said Kelvin Moses, Chief Financial Officer of Healthpeak. “We appreciate the continued support o.

Healthpeak Properties and Janus Living Announce Closing of Janus Living Initial Public Offering

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) (“Healthpeak”) and Janus Living, Inc. (NYSE: JAN) (“Janus Living”) announced today that Janus Living has completed its initial public offering of 48,300,000 shares of its Class A-1 common stock, which includes the exercise in full by the underwriters of their option to purchase up to an additional 6,300,000 shares of Class A-1 common stock, at a price to the public of $20.00 per share. Shares of Janus Living's Class A-1 common sto.

Healthpeak Properties and Janus Living Announce Pricing of Upsized $840 Million Janus Living Initial Public Offering

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) (“Healthpeak”) and Janus Living, Inc. (“Janus Living”) announced the pricing of Janus Living's upsized initial public offering (“IPO”) of 42,000,000 shares of Janus Living Class A-1 common stock at a price to the public of $20.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 6,300,000 shares of its Class A-1 common stock at the initial public offering price, less.